Ophthalmology
At BoFicher, we value the open exchange of communication between our therapeutic area leaders and your team. We encourage you to contact us to discuss your research plan and determine how we can support your development pathway.
With specific global experience in age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and several rare eye diseases, our team of experienced clinical research professionals is here to support your research and help improve the treatment landscape for ophthalmology patients.
Clinical Research Experience
Many of those breakthroughs result from advances in cell and gene therapy, a key area of specialization for BioFicher. Through our core competency in cell and gene therapy, BioFicher provides you with unique perspectives and expert insights into the latest research in AMD. From our work on the AREDS and AREDS 2 trials, to the gene therapy and stem cell studies we conduct today,BioFicher has supported clients at the forefront of AMD science. As a result of our collaborations, AREDS products are available to patients at risk for Advanced AMD.
Many of those breakthroughs result from advances in cell and gene therapy, a key area of specialization for BioFicher. Through our core competency in cell and gene therapy, BioFicher provides you with unique perspectives and expert insights into the latest research in AMD. From our work on the AREDS and AREDS 2 trials, to the gene therapy and stem cell studies we conduct today, BioFcher has supported clients at the forefront of AMD science. As a result of our collaborations, AREDS products are available to patients at risk for Advanced AMD.
BioFicher has also collaborated in the ongoing quest to develop methods for early diagnosis of diabetic retinopathy. We were proud to have supported the ophthalmology research efforts behind IDx-DR, which became the first FDA approved AI-based diagnostic system. The IDx-DR autonomously analyzes images of the retina for signs of diabetic retinopathy — a disease that blinds 23,000 people each year.
Biostatistics and Bioinformatics
Since our founding in by a biostatistician, BioFicher has been known as a “statistics-driven” CRO. We make it a point to involve biostatisticians across the clinical trial journey because we realize the value of high quality data and outcomes to our clients.
Ophthalmic studies present novel statistical challenges that often require analysis of correlated outcomes or estimating treatment effects for bilateral or unilateral diseases. BioFicher biostatisticians have developed robust novel analytical approaches for studies in rare ophthalmic diseases and have expertise analyzing visual outcomes.
If your ophthalmology study requires sophisticated analysis of genomic, proteomic, transcriptomic, metabolomic and other “omics” data analysis, you may wish to employ BioFicher’ biomedical data science & bioinformatics experts who can deliver a variety of solutions for you, including machine learning, advanced data visualization, pathways analysis, scalable cloud computing and reproducible data analysis methods.
Specialty Ophthalmic Products and Services
At BioFicher, we value the open exchange of communication between our therapeutic area leaders and your team. We encourage you to contact us to discuss your research plan and determine how we can support your development pathway.
Our history and proven outcomes working with multiple ophthalmic disease states, patient populations and recruitment strategies provide an optimal package for supporting your ophthalmology clinical research.
Patient
We are dedicated to improving the lives of patients fighting cardiovascular disease and critical illness
MORE ABOUT US
Ophthalmology Leaders
At BioFicher, we value the open exchange of communication between our therapeutic area leaders and your team. We encourage you to contact us to discuss your research plan and determine how we can support your development pathway.
Lisa Cummin, Ph.D.
Director and Biostatistician, Ophthalmic Therapeutic and Research Unit